Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06775665 | NOT YET RECRUITING | Hypertrophic Cardiomyopathy (HCM)

A Real-World Study on Hypertrophic Cardiomyopathy in the Chinese Population
Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary:

This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.

Condition or disease

Hypertrophic Cardiomyopathy (HCM)

Intervention/treatment

No interventions were applied to the patients.

Study Type : OBSERVATIONAL
Estimated Enrollment : 3000 participants
Official Title : Clinical Characteristics and Real-World Outcomes of Chinese Patients with Hypertrophic Cardiomyopathy: a Prospective Cohort Study
Actual Study Start Date : 2026-06-01
Estimated Primary Completion Date : 2031-01-01
Estimated Study Completion Date : 2032-06-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.
  • 2. Aged ≥18 years at the time of signing the written informed consent.
  • 3. Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria
    • 1. Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).
    • 2. Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.
    • 3. Exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening.
    Exclusion Criteria
    • 1. Uncontrolled primary hypertension.
    • 2. Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation.
    • 3. Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).
    • 4. Expected life expectancy \<1 years.
    • 5. Severe infections, liver failure, renal failure, or other life-threatening conditions.
A Real-World Study on Hypertrophic Cardiomyopathy in the Chinese Population

Location Details

NCT06775665

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Zhejiang

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, China, 310009